Journals
Publish with us
Publishing partnerships
About us
Blog
Canadian Journal of Gastroenterology and Hepatology
Journal overview
For authors
For reviewers
For editors
Table of Contents
Special Issues
Canadian Journal of Gastroenterology and Hepatology
/
2016
/
Article
/
Tab 49
/
Meeting Abstracts
Program and Abstracts from the Canadian Digestive Diseases Week
2016
Table 49
Incremental cost-effectiveness ratios for situations where adalimumab is readily available compared to when it is unavailable.
Time Horizon
Utility score of response to adalimumab measured by time-trade-off (
)
Utility score of response to adalimumab measured by visual rating scale (
)
5-year
$45,000 ($25,000–$65,000)
$40,000 ($22,000–$58,000)
10-year
$59,000 ($37,000–$81,000)
$53,000 ($33,000–$72,000)
15-year
$68,000 ($45,000–$91,000)
$60,000 ($40,000–$81,000)